Elevai Labs, Inc. (ELAB)

NASDAQ: ELAB · IEX Real-Time Price · USD
-0.07 (-3.29%)
At close: Dec 8, 2023, 4:00 PM
-0.10 (-4.85%)
After-hours: Dec 8, 2023, 7:39 PM EST
Market Cap 35.70M
Revenue (ttm) 1.03M
Net Income (ttm) -3.51M
Shares Out 17.33M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 349,520
Open 2.13
Previous Close 2.13
Day's Range 1.54 - 2.45
52-Week Range 1.54 - 4.24
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Dec 22, 2023

About ELAB

Elevai Labs is a physician-dispensed skincare company with a focus on modernizing aesthetic skincare. We conduct research and development to advance innovative and science-driven topical skincare that complements the medical aesthetics industry. Upon our founding in 2020, we initiated our research and development phase for our current product formulations. Since 2022, we have principally employed a business-to-business model in which we produce and commercialize a new generation of topical skincare products that contain our proprietary stem cel... [Read more]

IPO Date Nov 21, 2023
Employees 16
Stock Exchange NASDAQ
Ticker Symbol ELAB
Full Company Profile

Financial Performance

Financial Statements


ELEVAI Labs, Inc. Expands International Distribution into Europe

NEWPORT BEACH, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB), a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partn...

1 day ago - GlobeNewsWire

Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products

NEWPORT BEACH, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signe...

9 days ago - GlobeNewsWire

Elevai Labs IPO Registration Document (S-1)

Elevai Labs has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC